PMID- 12800983
OWN - NLM
STAT- MEDLINE
DCOM- 20030915
LR  - 20191107
IS  - 0803-8023 (Print)
IS  - 0803-8023 (Linking)
VI  - 1
DP  - 2003 May
TI  - Improved tolerability of the dihydropyridine calcium-channel antagonist 
      lercanidipine: the lercanidipine challenge trial.
PG  - 14-21
AB  - The objective of this 8-week open-label study was to compare the tolerability of 
      lercanidipine, a dihydropyridine calcium-channel antagonist (CA), with that of 
      other CAs in the treatment of hypertension. Subjects already taking amlodipine, 
      felodipine, nifedipine gastrointestinal therapeutic system (GITS), or 
      nitrendipine and experiencing CA-specific adverse effects (AEs) were switched to 
      lercanidipine for 4 weeks and then rechallenged with their initial treatment for 
      4 weeks. Results showed that at comparable levels of BP, lercanidipine was 
      associated with a significantly lower incidence of ankle edema, flushing, rash, 
      headache and dizziness compared with other CAs (p < 0.001). After 4 weeks of 
      lercanidipine, mean systolic blood pressure (SBP)/diastolic blood pressure (DBP) 
      was 142.1/86.7 mmHg. After rechallenge with other CAs for 4 weeks, mean SBP/DBP 
      was 141.1/86.7 mmHg. In this open-label study, lercanidipine compared with other 
      CA seems to provide a significant improvement in tolerability with comparable 
      antihypertensive effect.
FAU - Borghi, Claudio
AU  - Borghi C
AD  - Department of Internal Medicine, University of Bologna, Bologna, Italy. 
      claudio@med.unibo.it
FAU - Prandin, Maria Grazia
AU  - Prandin MG
FAU - Dormi, Ada
AU  - Dormi A
FAU - Ambrosioni, Ettore
AU  - Ambrosioni E
CN  - Study Group of the Regional Unit of the Italian Society of Hypertension
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PL  - Sweden
TA  - Blood Press Suppl
JT  - Blood pressure. Supplement
JID - 9300787
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Calcium Channel Blockers)
RN  - 0 (Dihydropyridines)
RN  - V7XTJ4R0BH (lercanidipine)
SB  - IM
MH  - Aged
MH  - Antihypertensive Agents/*adverse effects/*therapeutic use
MH  - Blood Pressure/drug effects
MH  - Calcium Channel Blockers/*adverse effects/*therapeutic use
MH  - Dihydropyridines/*adverse effects/*therapeutic use
MH  - Edema/chemically induced/epidemiology
MH  - Endpoint Determination
MH  - Female
MH  - Flushing/chemically induced/epidemiology
MH  - Headache/chemically induced/epidemiology
MH  - Heart Rate/drug effects
MH  - Humans
MH  - Hypertension/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Patient Dropouts
EDAT- 2003/06/13 05:00
MHDA- 2003/09/16 05:00
CRDT- 2003/06/13 05:00
PHST- 2003/06/13 05:00 [pubmed]
PHST- 2003/09/16 05:00 [medline]
PHST- 2003/06/13 05:00 [entrez]
AID - 10.1080/08038020310000087 [doi]
PST - ppublish
SO  - Blood Press Suppl. 2003 May;1:14-21. doi: 10.1080/08038020310000087.